Preclinical Development of Cellular Gene therapy using Viral Vector

为了发展细胞基因治疗肿瘤，我们成功地制备了表达IL-12的cGMP级腺病毒载体。我们还对使用经工程改造以高水平产生IL-12的树突状细胞的临床试验进行了临床前安全性检查。此外，作为基础研究，我们发现阻断MFG-E8（一种吞噬调理素）可以增强针对癌细胞的免疫应答。这些结果，包括临床级载体的产生、临床前安全性测试和进一步增强全身免疫反应的基础研究，使得能够开发治疗癌症的新方法。

In order to develop cellular-gene therapy against cancer, we have successfully produced cGMP-grade adeniviral vector expressing IL-12. We also performed preclinical safety examination for clinical trials using dendritic cells engineered to produce IL-12 at a high level. Furthermore, we have found the blockade of MFG-E8, an opsonin for phagocytosis, could enhance immune response against cancer cells as a basic research. These results, including generation of clinical grade vector, preclinical safety testing, and basic research to further enhance systemic immune responses, enables the development of novel approach to treat cancer.